Sean Glenn


Research Interests:

Understanding the genetic fingerprint of metastatic disease Animal models for study of cancer and metastasis (mouse/woodchuck) Pancreatic neuroEndocrine disease-Development and investigation of a novel mouse model to study cancer progression from primary disease through circulating tumor cell (CTC) involvement to metastasis Advanced genomic technologies for the study of cancer: Next-Generation Sequencing (NGS) including single-cell sequencing for study of CTCs Development of novel clinical approaches to identify actionable mutations from bio-fluids (CTCs, cfDNA/RNA) for diagnosis, prognosis, and treatment

About Sean Glenn


I received a Bachelor’s of Science in Biology from the State University of New York at Buffalo where I studied the RIP function in Neurospora crassa which is a duplication and mutation event localized to the premeiotic cells of the life cycle. I then went on to earn a Master’s of Science from the University at Buffalo focusing on transcriptional regulation of genes responsible for vascular development.

Furthermore, I received a PhD in Molecular and Cellular Biology from the Roswell Park Comprehensive Cancer Center Division of the University of Buffalo where, in the laboratory of Dr. Kenneth W. Gross, I developed a mouse model that mimics human metastatic pancreatic neuroendocrine carcinoma. This model, coupled with NGS technology, is a powerful tool for studying the cooperating mutations responsible for the evolution of metastatic disease including the identification and the role circulating tumor cells play in the progression of this process. This model also offers great promise for studying the pharmaceutical intervention of the metastatic phenotype.


Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Director, Genomics Shared Resource
  • Vice Chair, Molecular Pathology


Education and Training:

  • 2014 - PhD - Molecular and Cellular Biology – State University of New York at Buffalo, Buffalo, NY
  • 2002 - MS - Natural Sciences - State University of New York at Buffalo, Buffalo, NY


Full Publications list on PubMed
  • Pippin JW, Kaverina NV, Eng DG, Krofft RD, Glenn ST, Duffield JS, Gross KW, Shankland SJ. Cells of renin lineage are adult pluripotent progenitors in experimental glomerular disease. Am J Physiol Renal Physiol. 2015 Aug 15;309(4):F341-58. doi: 10.1152/ajprenal.00438.2014. Epub 2015 Jun 10. PMID: 26062877
  • Zhu Q, Hu Q, Shepherd L, Wang J, Wei L, Morrison CD, Conroy JM, Glenn ST, Davis W, Kwan ML, Ergas IJ, Roh JM, Kushi LH, Ambrosone CB, Liu S, Yao S. The Impact of DNA Input Amount and DNA Source on the Performance of Whole-Exome Sequencing in Cancer Epidemiology.Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1207-13. doi: 10.1158/1055-9965.EPI-15-0205. Epub 2015 May 19. PMID: 25990554
  • Glenn ST, Jones CA, Sexton S, LeVea CM, Caraker SM, Hajduczok G, Gross KW. Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma. Oncogene. 2014 Dec 11;33(50):5706-15. PubMed PMID: 24292676; PubMed Central PMCID: PMC4041964.
  • Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, Omilian AR, Hill A, Head K, Guru K, Kunnev D, Leach R, Eng KH, Darlak C, Hoeflich C, Veeranki S, Glenn S, You M, Pruitt SC, Johnson CS, Trump DL. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E672-81. PubMed PMID: 24469795; PubMed Central PMCID: PMC3926024.
  • Glenn ST, Jones CA, Gross KW, Pan L. Control of renin [corrected] gene expression. Pflugers Arch. 2013 Jan;465(1):13-21. PubMed PMID: 22576577; PubMed Central PMCID: PMC4370267.